Creative Biolabs is a world-leading antibody service provider. Aided by our advanced in vitro diagnostic (IVD) platform and long-term scientific expertise in the field of antibody discovery, we are able to provide the best-quality IVD antibody development services against various markers of esophageal cancer. Especially, Alcohol dehydrogenase isoenzyme (ADH IV) is one of the promising biomarkers of esophageal cancer and gastric cancer.
Alcohol dehydrogenases (ADH) are a group of dehydrogenase enzymes that can be divided into six classes (I-VI), displaying tissue specificity. ADH and ALDH (aldehyde dehydrogenase) are responsible for the metabolism of many biological substances such as ethanol, acetaldehyde, serotonin, retinol, etc. Besides, ADH is shown to facilitate the interconversion between alcohols and aldehydes or ketones with the reduction of nicotinamide adenine dinucleotide (NAD+) to NADH. ADH I and ADH IV are reported as principal participants of ethanol metabolism, and ADH IV forms the first barrier against exogenous ethanol in stomach and intestine mucosa. There are several different manifestations of major biochemical and physiological functions of ADH I and ADH IV have been reported: (1) defense against exogenous alcohols and some xenobiotics, detoxication of endogenous acetaldehyde and lipid peroxidation, (2) role in retinol oxidation, particularly during embryogenesis of adrenal glands and skin, (3) contribution to hydroxysteroids oxidation, (4) possible involvement in neuro-mediator metabolism, (5) effects on craving for ethanol.
Esophageal cancer (EC) is an aggressive upper gastrointestinal tract malignancy, which is the sixth most common cause of cancer-related death with high fatality rate and short survival. EC patients often present relatively late diagnosis, rapid clinical progression, and very poor patient survival. Therefore, the discovery of specific biomarkers that would detect malignant cells transformation as early as possible has attracted numerous attentions. ADH IV is detected in esophageal cancer cells with high enzyme activity compared with healthy mucosa. In addition, the activity of ADH IV in cancer cells is reflected in the sera and could thus be helpful for diagnosis of esophageal cancer, suggesting a potential significance of ADH IV as a marker of esophageal cancer.
Gastric cancer (GC) - also known as stomach cancer, often develops from the lining of the stomach. GC is a lethal disease that is often caused by Helicobacter pylori infection, accounting for more than 60%. It is reported that ADH IV is significantly higher in GC tissue. The sensitivity and specificity of ADH IV in GC patients is 73% and 79% respectively, indicating its potential role as a marker of gastric cancer.
Fig.1 Interconnected action of hepatic alcohol dehydrogenase (ADH) and the microsomal ethanol-oxidizing system (MEOS).1
ADH IV has been regarded as a candidate tumor marker of EC in both experimental and clinical applications. IVD antibodies against ADH IV marker present an independent prognostic and diagnostic value in EC patients and a potential application in therapeutic regimens. With advanced equipment and years of experience, Creative Biolabs can provide a whole set of antibody discovery and development services for clinical diagnosis. IVD antibody is an important branch of our portfolio, which can be customized for the development of different immunoassay formats, including ELISAs, immunohistochemistry, western blot, etc.
As a leading service provider, Creative Biolabs is specialized in production, purification, and characterization of different classes of IVD antibodies against specific biomarkers of EC. It is our honor to promote your brilliant studies and help you solve challenging problems in IVD antibody development. Please contact us for more information.
Reference
For Research Use Only.
